[go: up one dir, main page]

WO2024053899A1 - Procédé pour la production d'une structure d'assemblage de protéines multimères, et structure d'assemblage de protéines multimères produite selon ce procédé - Google Patents

Procédé pour la production d'une structure d'assemblage de protéines multimères, et structure d'assemblage de protéines multimères produite selon ce procédé Download PDF

Info

Publication number
WO2024053899A1
WO2024053899A1 PCT/KR2023/012192 KR2023012192W WO2024053899A1 WO 2024053899 A1 WO2024053899 A1 WO 2024053899A1 KR 2023012192 W KR2023012192 W KR 2023012192W WO 2024053899 A1 WO2024053899 A1 WO 2024053899A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
assembly structure
tag
multimeric
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/012192
Other languages
English (en)
Korean (ko)
Inventor
유태현
윤형돈
박예섭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajou University Industry Academic Cooperation Foundation
Original Assignee
Ajou University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajou University Industry Academic Cooperation Foundation filed Critical Ajou University Industry Academic Cooperation Foundation
Publication of WO2024053899A1 publication Critical patent/WO2024053899A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01026—2,5-Dioxovalerate dehydrogenase (1.2.1.26)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/0103—Glycerol dehydratase (4.2.1.30)

Definitions

  • the present invention relates to a method for producing a multimeric protein assembly structure that prevents excessive aggregation of multimeric proteins by controlling the expression of a protein containing a tag, and to the multimeric protein assembly structure produced thereby.
  • the formation of a complex through the assembly of intracellular proteins is a widely used method in the natural world, and it affects biological phenomena such as performing normal functions only by forming a complex or causing disease through complex formation, e.g.
  • the assembly of the capsid, a component of the shell of a virus, or the tau protein which is known to cause dementia.
  • Much research has been conducted on the assembly methods of natural proteins with various shapes and functions that are precisely manufactured, and as a result, various artificial self-assembling protein assembly methods have been developed.
  • the assembled complex has high applicability in biotechnology and medicine due to its high biocompatibility.
  • enzymes participating in the reaction are assembled to form a complex and then used. This allows efficient production of products by ensuring that the active sites between enzymes are located close together. Examples include pyruvate dehydrogenase complexes (PDCs) and cellulosomal complexes. Because the reaction by the complex places the active sites of the enzymes close together, the reaction can occur more quickly than when the related enzymes are simply mixed together. This has the advantage of allowing the reaction to occur before the diffusion of the reaction intermediate, preventing cell death due to intermediate toxicity if the intermediate is toxic, and preventing side reactions from occurring with other enzymes.
  • PDCs pyruvate dehydrogenase complexes
  • Spytag/Spycatcher a protein
  • FbaB fibronectin-binding protein
  • the Snooptag/Snoopcatcher pair was also developed based on a similar principle, and this orthogonal pair of two proteins was used to create an artificial complex of three enzymes of the mevalonate pathway, resulting in a five-fold increase in lycopene production and a two-fold increase in Escherichia coli. Increased astaxanthin production was confirmed.
  • RIDD and RIAD peptides derived from cAMP-dependent protein kinase (PKA) and A kinase-anchoring proteins (AKAPs) are also used to create artificial enzyme complexes.
  • a complex was created by fusing these peptides with two enzymes that connect the mevalonate pathway and the cartenoid pathway, and a 5.7-fold increase in carotenoid production in E. coli was confirmed.
  • artificial enzyme complexes using protein-based scaffolds such as Tobacco Mosaic Virus (TMV) virus-like particles (VLPs) and proliferating cell nuclear antigen (PCNA) proteins or DNA-based scaffolds
  • TMV Tobacco Mosaic Virus
  • VLPs virus-like particles
  • PCNA proliferating cell nuclear antigen
  • the present inventors manufactured an efficient multimeric protein assembly structure containing a tag by controlling the expression of the protein containing the tag using two different ribosome binding sites (RBS).
  • the present invention was completed by confirming that the multimeric protein assembly structure was used to prevent aggregation of excessive multimeric proteins and maximize the activity of the enzyme to increase the production of the target product (FIG. 2).
  • the purpose of the present invention is to prevent a decrease in protein activity or an increase in the proportion of proteins that have lost activity due to excessive assembly of proteins, especially when the tag is expressed in all monomers without control of tag expression by enzymes.
  • the present invention provides a method for producing an efficient multimeric protein assembly structure by controlling the expression of a protein containing an efficient tag by controlling the translation start point, and a multimeric protein assembly structure produced thereby.
  • the present invention provides (a) a first gene construct comprising a gene encoding a first target protein and a gene encoding a first tag protein, a gene encoding a second target protein, and a second A recombinant microorganism into which a second gene structure containing a gene encoding a tag protein, a first ribosome binding site, and a second ribosome binding site is introduced is cultured, and the first target protein multimer and the second target protein multimer are covalently linked. generating a multimeric protein assembly structure linked by; and (b) recovering the generated multimeric protein assembly structure.
  • the present invention also provides a multimeric protein assembly structure prepared by the above method.
  • Figure 1 is a schematic diagram showing a problem with existing technology that may cause excessive aggregation during the production of multimeric proteins.
  • Figure 2 is a schematic diagram of a method for controlling the expression of a protein containing a tag.
  • a multimeric protein assembly structure containing an efficient tag is manufactured by controlling the translation start point at the N terminus of the protein using two ribosome binding sites.
  • Figure 3 is a schematic diagram showing that in enzyme reactions that occur simultaneously, side reactions may occur due to intermediates or unwanted products may be generated, which may affect the production of the desired product.
  • Figure 4 is a schematic diagram showing that a rapid reaction can occur by preventing side reactions from intermediates with other enzymes during a reaction using an enzyme complex.
  • FIG. 5 is a schematic diagram of a reaction involving pyruvate dehydrogenase complexes (PDCs), as an example of how related enzymes naturally form complexes and use them in reactions to efficiently produce various compounds.
  • PDCs pyruvate dehydrogenase complexes
  • Figure 6 shows the formation of an enzyme complex using a monomer and the formation of a multimeric enzyme complex using an enzyme with an efficient tag.
  • Figure 7 shows the production path of 3-hydroxypropionic acid (3-HP).
  • Glycerol dehydratase and Aldehyde dehydrogenase are enzymes, and 3-hydroxypropionaldehyde (3-HPA) is a toxic intermediate.
  • Figure 8 illustrates that by preparing an artificial enzyme complex using the technology of the present invention, the diffusion of 3-HPA, an intermediate, can be reduced and the final production of 3-HP can be increased.
  • Figure 9 shows the structure and binding principle of spytag (ST)/spycatcher (SC), which was created by isolating the fibronectin-binding protein FbaB from Streptococcus pyogenes as an example of the tag protein pair of the present invention, and their amino acid sequences ( PNAS 2012, 109 (12), E690-E697 and PNAS 2019, 116 (52), 26523-26533).
  • Figure 10 shows a gene form in which ST, ST3, and SC3 are fused to the C-terminus of the first enzyme, glycerol dehydratase (GDHt), and the second enzyme, alpha-ketoglutaric semialdehyde dehydrogenase ( ⁇ -ketoglutaric).
  • GDHt glycerol dehydratase
  • ⁇ -ketoglutaric alpha-ketoglutaric semialdehyde dehydrogenase
  • Figure 11 shows the results of comparing the activities of an enzyme containing a tag and an enzyme without a tag, and the results of measuring ST/SC binding between enzymes.
  • Figure 12 shows the results of observing the change in NADH produced when 3-HP is produced by adding glycerol and the two enzymes GDHt and KGSADH through absorbance at 340 nm.
  • Figure 13 shows a schematic diagram of a structure in which five solubility-enhancing tag candidates (ubiquitin, Z domain, CMB66, Trx, Fh8) were additionally fused to the KGSADH structure (ST-K) and the results of comparing the solubility with the existing structure.
  • solubility-enhancing tag candidates ubiquitin, Z domain, CMB66, Trx, Fh8
  • Figure 14 shows the results of measuring the activity of ST-K enzyme and ST/SC binding between enzymes depending on the presence or absence of the solubility-enhancing tag Z-domain.
  • Figure 15 shows the results of analyzing 3-HP production after expression by lowering the concentration of IPTG, an inducer used in protein expression, from 0.1mM, which is the existing condition, to 0.01mM.
  • Figure 16 shows the separation of two enzymes expressed during 3-HP production (the first enzyme is IPTG inducible, the second enzyme is arabinose inducible) to be expressed by different inducers, and then the concentration of each inducer is adjusted to produce 3-HP. It shows the results of the analysis.
  • enzymes exist as monomers or as multimers made by combining monomers. Manufacturing enzyme complexes using monomeric enzymes is easy to manufacture and use because each enzyme forms an enzyme complex at a 1:1 ratio, but if all monomers forming the multimer have tags for assembly, excessive assembly between enzymes may occur. As a result, enzyme aggregation may occur and the enzyme activity may be reduced or lost ( Figure 1). In addition, enzyme reactions occur simultaneously and side reactions may occur due to intermediates or undesirable products may be generated, which may affect the production of the desired product ( Figure 3).
  • the present inventors manufactured an efficient multimeric protein assembly structure containing the tag by controlling the expression of the protein containing the tag using two different ribosome binding sites (RBS). It was confirmed that using the multimeric protein assembly structure, aggregation of excessive multimeric proteins was prevented and side reactions caused by intermediates in the enzyme reaction were minimized to increase the production of the target product (FIG. 2).
  • the multimeric protein assembly structure of the present invention positions the active sites of enzymes close to each other to prevent side reactions from intermediates with other enzymes during the reaction, allowing a rapid reaction to occur and minimizing the diffusion of intermediates to increase the production of target products. ( Figures 4 and 8).
  • the present invention provides (a) a first gene construct comprising a gene encoding a first target protein and a gene encoding a first tag protein, and a gene encoding a second target protein, and a second tag.
  • a first gene construct comprising a gene encoding a first target protein and a gene encoding a first tag protein, and a gene encoding a second target protein, and a second tag.
  • the present invention relates to a multimeric protein assembly structure produced by the method for producing the multimeric protein assembly structure.
  • the number of first target protein multimers linked to each second target protein multimer may be 1 to 4.
  • the second gene construct may be characterized in that it sequentially includes a first ribosome binding site, a gene encoding a second tag protein, a second ribosome binding site, and a gene encoding a second target protein. there is.
  • the second genetic construct may additionally include a gene encoding a third tag protein.
  • the second gene construct includes a first ribosome binding site, a gene encoding a third tag protein, a gene encoding a second tag protein, a second ribosome binding site, and a gene encoding a second target protein. They may be included sequentially, and the third tag may be a Z-domain.
  • the target protein may be an enzyme.
  • the first target protein is glycerol dehydratase (GDHt)
  • the second target protein is alpha-ketoglutaric semialdehyde dehydrogenase (KGSADH). You can.
  • the first tag and the second tag may be Spytag (ST) and Spycathcer003 (SC3), or Spycathcer003 (SC3) and Spytag (ST), respectively.
  • the covalent bond may be an isopeptide bond.
  • expression of the target protein fused to the tag protein can be performed by controlling the translation start point.
  • the translation start point can be performed using two ribosome binding sites.
  • using two ribosome binding sites means, for example, changing the ribosome binding site sequence.
  • oline tools such as UTR designer predict the expression level of a protein when the ribosome binding site has a specific sequence.
  • the initiation of translation can be controlled by changing the sequence of the two ribosome binding sites in the gene construct and controlling the strength of the ribosome binding site strength. Therefore, a target protein multimer can be synthesized through the target protein and/or the target protein fused to the tag protein by expressing only the target protein or the tag protein in the gene construct of the present invention.
  • the method for producing the multimeric protein assembly structure includes the steps of randomly causing mutations in the two ribosome binding sites to produce a library and screening or selecting the library; And it may be characterized by further comprising the step of finding a ribosome binding site when producing a target protein and a tag protein assembly including an efficient tagged protein.
  • the regulation of the translation start point may be characterized as being carried out at the N-terminus of the protein, but is not limited thereto.
  • Regulation of the translation start point can be performed using two ribosome binding sites present on both sides of the nucleic acid sequence expressing the tagged protein. Since single-stranded RNA such as mRNA can form a specific structure by itself, the specific structure of mRNA can be modified depending on the ribosome binding site and the nucleic acid sequence surrounding it, and the strength at which the ribosome can bind accordingly may vary.
  • the number of tags on the target protein can be adjusted by adjusting the nucleic acid sequences surrounding the two ribosome binding sites using an untranslated region (UTR) designer, and at this time, the 5'-UTR sequence and protein coding
  • the number of tags on the target protein can be adjusted by adjusting the sequence, 16s rRNA sequence, etc. (https://sbi.postech.ac.kr/utr_designer/).
  • the control of the translation start point is also carried out by randomizing the surrounding nucleic acid sequences of the two ribosome binding sites to create a library and then selecting strains with increased protein expression using a multimeric protein assembly structure. It can also be adjusted through research to find the appropriate combination.
  • the increase in protein expression according to the ribosome binding site is achieved by expressing the protein in the cell and measuring the intensity of the band through SDS-PAGE by taking advantage of the difference in the band positions of the tagged and untagged proteins. This can be analyzed qualitatively.
  • target protein or “heterologous protein” in the present invention refers to a protein that a trader wishes to produce in large quantities, and is expressed in a transformant by inserting a polynucleotide encoding the protein into a recombinant vector. This means all possible proteins.
  • the target protein may be one or more selected from the group consisting of antigen, antibody, cell receptor, enzyme protein, structural protein, serum, and cell protein, but is not limited thereto.
  • the target protein may include, but is not limited to, glycerol dehydratase (GDHt) and/or alpha-ketoglutaric semialdehyde dehydrogenase (KGSADH). .
  • GDHt glycerol dehydratase
  • KGSADH alpha-ketoglutaric semialdehyde dehydrogenase
  • GDHt glycerol dehydratase
  • ⁇ -ketoglutaric semialdehyde dehydrogenase is a reaction that converts 3-HPA to 3-hydroxypropionic acid (3-HP). It is a type of oxidoreductase that catalyzes, and when 3-HP is produced, NADH is also produced.
  • 3-HP is used as a raw material to produce acrylic acid, acrylamide, 1,3-propanediol, and malonic acid, which are used in various chemical processes, and is also used to synthesize biodegradable polymers.
  • Biological production of 3-HP using glycerol has been successfully achieved through genetic manipulation of key enzymes required for the 3-HP production pathway in various bacteria, but it has been difficult to further increase 3-HP production.
  • enzymes such as GDHt and KGSADH become unstable or lose their activity, and when GDHt exists together with 3-HPA, its activity decreases depending on the concentration of 3-HPA. Problems are being observed.
  • an inducer may be used during protein expression.
  • the “inducer” can be anything that can increase the expression level of a protein, and can be selected from the group consisting of IPTG, arabinose, anhydrotetracycline (ATC), and doxycycline (DOX), but is not limited thereto. .
  • the concentration of the inducer may be 1mM or less, 0.1mM or less, 0.01mM or less, or 0.001mM or less, and may be 1% or less, 0.1% or less, 0.01% or less, or 0.001% or less. It is not limited.
  • tag protein refers to a peptide sequence genetically transferred to a recombinant protein. Tags are attached to proteins for various purposes. Typically, a tag protein is attached to a protein to facilitate detection and purification of the expressed protein. It can also be used to construct fusions of a protein of interest with another protein. In the present invention, when forming a multimeric protein assembly structure or an enzyme assembly structure, a target protein fused to a tag protein may be used, but is not limited thereto.
  • the tag protein may be selected from the group consisting of Spytag/Spycatcher, Snooptag/Snoopcatcher, and RIDD/RIAD peptide, but is not limited thereto.
  • the tag protein may be linked to the N-terminus of the target protein, but is not limited thereto.
  • the “third tag protein” can be additionally fused to the above gene construct to improve the solubility of the enzyme, and includes ubiquitin, Z-domain, CMB66, Trx, Fh8, MBP, NusA, SUMO, GST, SET, It may be selected from the group consisting of GB1, HaloTag, SNUT, Skp, T7PK, EspA, Mocr, Ecotin, CaBP, ArsC and IF2-domain I, preferably Z-domain, but is not limited thereto.
  • the GDHt may be characterized as comprising the amino acid sequence of SEQ ID NO: 1 or 3.
  • nucleic acid sequence encoding GDHt may be characterized as comprising the base sequence of SEQ ID NO: 2 or 4.
  • the construct (Z-ST-K) in which Spytag (ST) and Z-domain are additionally fused to KGSADH may be characterized by expressing an amino acid sequence including the amino acid sequence of SEQ ID NO: 5.
  • nucleic acid sequence of the construct (Z-ST-K) in which Spytag (ST) and Z-domain are additionally fused to KGSADH may be characterized as comprising the base sequence of SEQ ID NO: 6.
  • the tag protein may be characterized as comprising the amino acid sequence of SEQ ID NO: 7, 8, 9, or 10.
  • the nucleic acid sequence encoding the tag protein may include the base sequence of SEQ ID NO: 11, 12, 13, or 14.
  • the control of the translation start point can be performed using two ribosome binding sites present on both sides of the nucleic acid sequence of the KGSADH gene construct expressing the tagged protein. Specifically, refer to [Table 2] below for the specific sequences and predicted expression levels of the 5'-UTRs of RBS1 and RBS2 of the KGSADH gene construct.
  • gene construct refers to recombinant DNA manufactured for introduction into cells.
  • the construct contains several genes (functional genes, marker genes, appropriate regulatory genes) and is generally used for GMO production. It refers to the functional unit required for the transfer or expression of a desired gene.
  • the gene encoding the target protein and the gene encoding the tag protein may be connected directly or through a linker.
  • translation refers to the binding of a ribosome complex to mRNA to synthesize a protein in the 5' to 3' direction.
  • a stop codon is located at the A site of the ribosome, a release factor binds, the ribosome complex is released, and translation is terminated.
  • multimer refers to a protein molecule made up of two or more polypeptide units.
  • multimeric protein refers to a protein molecule that performs a specific function by combining two or more different protein molecules.
  • ribosome binding site refers to a ribosome binding site that allows mRNA transcribed from DNA to bind to ribosomes in the host cell when protein biosynthesis begins.
  • it is called the Shine-Dalgarno sequence. It is generally located 8 bases before the start codon AUG. This RNA sequence attracts ribosomes to the mRNA and aligns the ribosomes at the start codon site, helping to initiate protein synthesis.
  • the ribosome binds to the 5'cap portion of the mRNA and scans from 5' to 3' until it encounters the start codon. Translation begins after encountering the start codon.
  • assembly in the present invention means that each component forms a certain structure spontaneously or through specific combinations.
  • protein assembly means combining two or more proteins to form a certain structure.
  • assembly may be used interchangeably with complex or fusion.
  • complex refers to an object made up of two or more objects.
  • protein complex may refer to a protein set in which two or more proteins can come together and have a variety of functions.
  • One protein molecule that makes up this complex is called a “subunit.”
  • fusion in the present invention means combining different types of things into one state.
  • protein fusion refers to a protein in which a target protein and a tag protein are combined.
  • the present invention is applicable to any protein desired by those skilled in the art, and in particular, proteins for medical, research and industrial use, such as antigens, antibodies, cell receptors, enzymes, structural proteins, serum, and cell proteins selected from the group consisting of Various target proteins with biological activity can be expressed in the form of recombinant proteins, but are not limited thereto.
  • step (a) may be characterized by cultivating a recombinant microorganism or host cell into which the first and second genetic constructs have been introduced.
  • the genetic construct may be inserted into the chromosome of a recombinant microorganism or host cell, or the recombinant vector to which the genetic construct is operable may be inserted into the recombinant microorganism or host cell. You can do this.
  • commonly known genetic manipulation methods can be used as a method for inserting the genetic construct into the chromosome of a recombinant microorganism or host cell, for example, retroviral vectors, adenovirus vectors, and adeno-associated viruses. It can be inserted into the chromosome of a host cell by using a vector, herpes simplex virus vector, poxvirus vector, lentivirus vector, or non-viral vector, but is not limited thereto.
  • prokaryotic cells such as Escherichia coli and Bacillus subtillis have been widely used as the host cells.
  • a single-celled eukaryotic cell the yeast family (Pichia pastoris, Saccharomyces cerevisiae, Hansenulapolymorpha, etc.), filamentous fungi, insect cells, plant cells, and mammalian cells are used as host cells for recombinant protein production, so E. coli or Those skilled in the art can easily use not only recombinant microorganisms but also other host cells.
  • CHO cell line, HEK cell line, etc. can be used as host cells for expression, but are not limited thereto.
  • the recombinant microorganism is Escherichia coli, Rhizobium, Bifidobacterium, Rhodococcus, Candida, Erwinia, Enterobacter, and Paste.
  • Pasteurella Mannheimia, Actinobacillus, Aggregatibacter, Xanthomonas, Vibrio, Pseudomonas, Azotobacter, Acinetobacter, Ralstonia, Agrobacterium, Rhodobacter, Zymomonas, Bacillus, Staphylococcus, Lactococcus ( Lactococcus, Streptococcus, Lactobacillus, Clostridium, Corynebacterium, Streptomyces, Bifidobacterium, Cyanobacterium ( It may be characterized as being selected from the group consisting of Cyanobacterium) and Cyclobacterium, but is not limited thereto.
  • microorganism in the present invention refers to organisms that are so small that they cannot be observed with the naked eye. Microorganisms are organisms that, even if single-celled or multicellular, have no morphological or functional differentiation between cells and can live independently even as single cells.
  • “recombinant microorganism” refers to a microorganism into which the above genetic construct or vector containing the genetic construct has been introduced to produce a multimeric protein complex.
  • the recombinant vector is a recombinant vector linked so that a first genetic structure is operable to synthesize a first target protein multimer and/or a second genetic construct is operable to synthesize a second target protein multimer. It may be a recombinant vector linked to do so.
  • vector refers to a nucleic acid preparation containing a nucleic acid sequence operably linked to a suitable expression control sequence capable of expressing a gene in a suitable host.
  • Vectors can be plasmids, phage particles, or simply potential genomic inserts. Once transformed into a suitable host, the vector can replicate and function independently of the host genome, or in some cases can be integrated into the genome itself. Since plasmids are currently the most commonly used form of vector, “plasmid” and “vector” are sometimes used interchangeably in the context of the present invention. However, the present invention includes other forms of vectors with equivalent functionality as are known or become known in the art. Protein expression vectors used in E.
  • coli include the pET series, pCDF series, pRSF series, pACYC series and pCOLA series from Novagen (USA); pBAD series from Invitrogen (USA); pHCE or pCOLD from Takara (Japan); pACE series from GenoFocus (Korea); pTac15K, pTrc99A, pTacCDFS, and pTrcCDFS lines from KAIST (Republic of Korea); The pBBR1MCS series, which can be used in a wide range of strains, can be used.
  • protein expression can be realized by inserting a target gene into a specific part of the genome, or a pHT series vector from MoBiTech (Germany) can be used. Protein expression is also possible in mold and yeast using genome insertion or self-replicating vectors. Protein expression vectors for plants can be used using the T-DNA system such as Agrobacterium tumefaciens or Agrobacterium rhizogenes. Typical expression vectors for mammalian cell culture expression are based for example on pRK5 (EP 307,247), pSV16B (WO 91/08291) and pVL1392 (Pharmingen).
  • the recombinant vector can be introduced into a microorganism by a method such as transformation, but is not limited thereto.
  • transformation refers to the introduction of DNA into a host so that the DNA can be replicated as an extrachromosomal factor or through completion of chromosomal integration.
  • Any transformation method can be used and can be easily performed according to conventional methods in the art.
  • transformation methods include the CaCl2 precipitation method, the Hanahan method, which increases efficiency by using a reducing substance called DMSO (dimethyl sulfoxide) in the CaCl2 method, electroporation, calcium phosphate precipitation, protoplast fusion method, and silicon carbide fiber.
  • Stirring method, Agrobacteria-mediated transformation method, transformation method using PEG, dextran sulfate, lipofectamine, and drying/inhibition-mediated transformation method may be used, but are not limited thereto.
  • operably linked means that the linked DNA sequences are in contact and, in the case of a secretory leader, in contact and within reading frame. However, the enhancer need not be in contact. Linking of these sequences is accomplished by ligation at convenient restriction enzyme sites. If such a site does not exist, a synthetic oligonucleotide adapter or linker is used according to a conventional method.
  • the recombinant vector may further include a promoter.
  • the promoter may be selected from the group consisting of trc promoter, tac promoter, T7 promoter, lactose promoter, and trp promoter, but is not limited thereto.
  • promoter refers to the upstream region of a gene involved in the initiation of transcription (the step of synthesizing RNA from DNA). In other words, it refers to the part of the DNA strand where RNA Polymerase binds or the part where RNA complementary to one strand of DNA is synthesized, that is, transcription begins.
  • the recombinant vector may additionally include a terminator to increase the reliability and efficiency of transcription.
  • terminal refers to a region of a gene involved in transcription termination.
  • the terminator is, for example, CaMV 35S terminator, nopaline synthase (NOS), rice ⁇ -amylase RAmy1 A terminator, phaseoline terminator, Octopine gene of Agrobacterium tumefaciens. It may include terminators, E. coli rrnB1/B2 terminators, T7 terminators, etc., but is not limited thereto.
  • culture refers to cultivating microorganisms to induce the desired effect, and the desired effect of the present invention is to prevent excessive aggregation of proteins by preparing an assembly structure of the target protein and the tagged protein.
  • the culture may generally be carried out in a culture medium suitable for the microorganism used and containing at least one simple carbon source and, if necessary, a co-substrate, but is not limited thereto.
  • the synthesis of the target protein multimer may be performed by an in vitro or cell-free protein synthesis method, but is not limited thereto.
  • Protein production methods have mainly been used to destroy the cytoplasm of living cells or to chemically polymerize amino acids.
  • the above methods require very complex production processes in terms of cell disruption and purification/separation, and the produced proteins are not expressed normally or are not well accepted by the body and cause an immune response, and amino acids are involved in the polymerization of long-chain proteins. It had disadvantages such as poor sequencing accuracy. Therefore, in recent years, the development of a cell-free or in vitro protein synthesis system that does not use cells in the peptide or protein production process is actively underway.
  • step (a) may be characterized by synthesizing the first target protein multimer and/or the second target protein multimer using a cell-free protein synthesis method.
  • cell-free or in vitro protein synthesis method refers to “cell-free or in vitro synthesis method” or “cell-free peptide synthesis method” depending on the production target. (cell-free or in vitro peptide synthesis method)' or 'cell-free protein/peptide synthesis method' can be used interchangeably with the same meaning.
  • cell-free protein synthesis method refers to the addition of substrates or enzymes to cell lysates or extracts to obtain key elements (ATP (adenosine triphosphate), amino acids, etc.) required for protein synthesis. ) refers to a method of synthesizing proteins in a test tube using .
  • This cell-free protein synthesis method can overcome the shortcomings of existing protein production methods using cells, and cell-free protein synthesis only uses the intracellular machinery and its factors involved in protein production in cells. By extracting and artificially repeating the protein synthesis process outside the cell, excluding the physiological control mechanism of the cell, the target protein can be mass-produced in a short period of time.
  • the cell membrane can also be synthesized.
  • the cell membrane can also be synthesized.
  • intracellular protein synthesis methods have major problems with production and yield when the produced proteins are cytotoxic.
  • cell-free protein synthesis methods are used, peptides or proteins can be produced without these problems.
  • it is expected to increase productivity because it can be free from various external conditions such as pH, temperature, and ionic strength when synthesizing proteins.
  • Spytag and spycatcher spontaneously form isopeptide bonds. This protein pair was first reported in 2012, and in 2019, version 003 of spytag003/spycatcher003, which can form bonds even at low concentrations, was reported (PNAS 2012, 109 (12), E690-E697 and PNAS 2019, 116 ( 52), 26523-26533).
  • a first gene construct and a second gene construct containing sequences encoding the selected tag protein pair were prepared.
  • the first gene construct prepared in Example 2 was inserted into the pDK7 vector to construct a recombinant vector expressing GDHt.
  • the second gene construct prepared in Example 2 was inserted into the pQE80L vector to construct a recombinant vector expressing KGSADH.
  • GDHt and KGSADH fused with the tagged protein obtained after culturing were purified through affinity chromatography using a Histidine*6 tag.
  • Example 4-1 Enzyme activity of GDHt and KGSADH fused with tag protein
  • Example 4-2 Comparison of conjugation between tags of GDHt and KGSADH fused with tag proteins
  • Example 5 Measurement of 3-HP production rate through assembly structure of GDHt and KGSADH fused with tag protein
  • Example 6 Assembly structure of GDHt and KGSADH with solubility-enhancing tags to improve enzyme solubility
  • Example 6-1 Selection of tags to improve enzyme solubility
  • Example 2 In a similar manner to Example 2, a genetic construct containing a sequence encoding five candidate tags (ubiquitin, Z domain, CMB66, Trx, Fh8) for improving enzyme solubility was prepared. Afterwards, the enzyme solubility was measured together with the gene construct prepared in Example 2. At this time, only the soluble enzyme was shown to be active, and only one RBS was fused to the gene construct so that the tag was expressed on all monomers of the enzyme.
  • candidate tags ubiquitin, Z domain, CMB66, Trx, Fh8
  • Example 6-2 Comparison of enzyme activity and conjugation between tag ST-SC according to the presence or absence of Z-domain
  • Example 7 Analysis of conditions for increasing 3-HP production through assembly structures of GDHt and KGSADH fused with tag proteins
  • Example 7-1 Increase in 3-HP production depending on the concentration of IPTG
  • modified M9 media for 100mM glycerol
  • modified M9 media contained 2g/L of NH4Cl, 2g/L of NaCl, 1g/L of yeast extract, 0.5g/L of MgSO4, and It consists of 100mM pH7 potassium phosphate.
  • E. coli (W strain) colonies into which two vectors (pDK7-GDHt-SC3 and pQE80L-RBS1-Z domain-RBS2-KGSADH) were introduced were inoculated into test tubes and grown overnight.
  • OD600 1
  • OD600 0.8 ⁇ 0.9, 0.01mM IPTG, an inducer, was added for protein expression.
  • 3-HP production at 4 hours, 8 hours, 18 hours, and 24 hours was analyzed and compared through HPLC (Aminex HPX-87H).
  • Example 7-2 Increase in 3-HP production according to IPTG and arabinose
  • GDHt and KGSADH were separately expressed by different inducers (IPTG and arabinose, respectively), and each protein was expressed by further lowering the concentration of IPTG, the inducer of GDHt, to 0.001mM and arabinose, the inducer of KGSADH, to 0.0002%. After this, it was measured whether 3-HP production was increased through the multimeric protein assembly structure of the present invention.
  • modified M9 media for 100mM glycerol
  • modified M9 media contained 2g/L of NH4Cl, 2g/L of NaCl, 1g/L of yeast extract, 0.5g/L of MgSO4, and It consists of 100mM pH7 potassium phosphate.
  • E. coli (W strain) colonies into which two vectors (pDK7-GDHt-SC3 and pQE80L-RBS1-Z domain-RBS2-KGSADH) were introduced were inoculated into test tubes and grown overnight.
  • OD600 0.8 ⁇ 0.9, 0.001mM IPTG and 0.0002% arabinose as inducers were added for protein expression.
  • 3-HP production at 4 hours, 8 hours, 18 hours, and 24 hours was analyzed and compared through HPLC (Aminex HPX-87H).
  • the multimeric assembly structure of the present invention can maximize the effect between enzymes to suppress the diffusion of intermediates in the reaction and increase the production of the target product.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de production d'une structure d'assemblage de protéines multimères, comprenant les étapes suivantes : (a) production d'une structure d'assemblage de protéines multimères dans laquelle un premier multimère protéique cible et un second multimère protéique cible sont reliés par une liaison covalente en cultivant un micro-organisme recombiné dans lequel une première structure génique et une seconde structure génique sont introduites, la première structure génique comprenant un gène codant pour une première protéine cible et un gène codant pour une première protéine de marquage, et la seconde structure génique comprenant un gène codant pour une seconde protéine cible, un gène codant pour une seconde protéine de marquage, un premier site de liaison au ribosome, et un second site de liaison au ribosome ; et (b) collecte de la structure d'assemblage de protéines multimères produite. L'invention concerne également une structure d'assemblage de protéines multimères produite selon le procédé de production de structure d'assemblage de protéines multimères.
PCT/KR2023/012192 2022-09-06 2023-08-17 Procédé pour la production d'une structure d'assemblage de protéines multimères, et structure d'assemblage de protéines multimères produite selon ce procédé Ceased WO2024053899A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0112724 2022-09-06
KR20220112724 2022-09-06

Publications (1)

Publication Number Publication Date
WO2024053899A1 true WO2024053899A1 (fr) 2024-03-14

Family

ID=90191416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/012192 Ceased WO2024053899A1 (fr) 2022-09-06 2023-08-17 Procédé pour la production d'une structure d'assemblage de protéines multimères, et structure d'assemblage de protéines multimères produite selon ce procédé

Country Status (2)

Country Link
KR (1) KR20240034646A (fr)
WO (1) WO2024053899A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070077140A (ko) * 2006-01-20 2007-07-25 연세대학교 산학협력단 단백질-단백질의 상호작용을 분석하는 방법
KR20190083307A (ko) * 2018-01-03 2019-07-11 경상대학교산학협력단 목적 단백질의 수용성 및 발현량 증가를 위한 융합 태그 및 이의 용도
KR20210069271A (ko) * 2019-12-03 2021-06-11 전남대학교산학협력단 스플릿 인테인을 접목한 가용성 향상 이중 기능성 융합 태그를 이용한 재조합 섬유아세포 성장인자 수용체의 제조방법, 정제방법, 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070077140A (ko) * 2006-01-20 2007-07-25 연세대학교 산학협력단 단백질-단백질의 상호작용을 분석하는 방법
KR20190083307A (ko) * 2018-01-03 2019-07-11 경상대학교산학협력단 목적 단백질의 수용성 및 발현량 증가를 위한 융합 태그 및 이의 용도
KR20210069271A (ko) * 2019-12-03 2021-06-11 전남대학교산학협력단 스플릿 인테인을 접목한 가용성 향상 이중 기능성 융합 태그를 이용한 재조합 섬유아세포 성장인자 수용체의 제조방법, 정제방법, 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTHONY H. KEEBLE, PAULA TURKKI, SAMUEL STOKES, IRSYAD N. A. KHAIRIL ANUAR, ROLLE RAHIKAINEN, VESA P. HYTöNEN, MARK HOWARTH: "Approaching infinite affinity through engineering of peptide–protein interaction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 116, no. 52, 26 December 2019 (2019-12-26), pages 26523 - 26533, XP055723018, ISSN: 0027-8424, DOI: 10.1073/pnas.1909653116 *
ASHLEY R. SUTHERLAND; MD. KAUSAR ALAM; C. RONALD GEYER: "Post‐translational Assembly of Protein Parts into Complex Devices by Using SpyTag/SpyCatcher Protein Ligase", CHEMBIOCHEM, JOHN WILEY & SONS, INC., HOBOKEN, USA, vol. 20, no. 3, 6 December 2018 (2018-12-06), Hoboken, USA, pages 319 - 328, XP072201079, ISSN: 1439-4227, DOI: 10.1002/cbic.201800538 *

Also Published As

Publication number Publication date
KR20240034646A (ko) 2024-03-14

Similar Documents

Publication Publication Date Title
EP0856059B1 (fr) Procede de production de plasmides de recombinaison
US5252466A (en) Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them
Van Heeke et al. Expression of human asparagine synthetase in Escherichia coli
Qian et al. Proteome‐based identification of fusion partner for high‐level extracellular production of recombinant proteins in Escherichia coli
US20070248536A1 (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
JPH06500006A (ja) ユビキチン特異的プロテアーゼ
US20210002626A1 (en) Universal Platform for Genetic Code Expansion
EP3506945A1 (fr) Production de séléno-biologiques dans des organismes génétiquement recodés
US20240263209A1 (en) Composition of transfer rnas and use in production of proteins containing non-standard amino acids
EP3330282A1 (fr) Cipa et cipb pixa comme échafaudages pour organiser des protéines dans des inclusions cristallines
Lee et al. Development of orthogonal aminoacyl tRNA synthetase mutant with enhanced incorporation ability with para-azido-L-phenylalanine
CN100567501C (zh) 在芽孢杆菌细胞的色素缺陷突变体中产生生物物质的方法
Ghosh et al. Arginine-395 is required for efficient in vivo and in vitro aminoacylation of tRNAs by Escherichia coli methionyl-tRNA synthetase
KR100690948B1 (ko) 대장균의 외막 단백질을 이용한 목적 단백질의 미생물표면발현 방법
WO2024053899A1 (fr) Procédé pour la production d'une structure d'assemblage de protéines multimères, et structure d'assemblage de protéines multimères produite selon ce procédé
CN118891361A (zh) 具有改善的耐盐性和/或温度性能的核酸酶
EP1497431A2 (fr) Cellule hote de bacille amelioree
Botterman et al. Characterization of phosphinothricin acetyltransferase and C-terminal enzymatically active fusion proteins
WO2022214065A1 (fr) Protéine chimérique modificatrice d'arn et son application
AU5827090A (en) Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
JP2545377B2 (ja) Ｄｎａ配列体
CN112888787A (zh) 新型细菌lpp突变体及其在重组蛋白质的分泌生产中的用途
Roy et al. Use of a coupled transcriptional system for consistent overexpression and purification of UDG–ugi complex and Ugi fromEscherichia coli
WO2025005612A1 (fr) Procédé pour la production de méthane monooxygénase sélective à haute efficacité par l'intermédiaire de sigma-54 et de mmor
CN119752838B (zh) 耐热高产的t7 rna聚合酶突变体及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23863376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23863376

Country of ref document: EP

Kind code of ref document: A1